Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
- Conditions
- Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Antisoma Research
- Target Recruit Count
- 420
- Registration Number
- NCT00715637
- Locations
- 🇺🇸
UCLA Medical Center, Los Angelas, California, United States
🇺🇸Univ of Southern California Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
- Conditions
- Chronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)
- Interventions
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 192
- Registration Number
- NCT00710528
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 52
- Registration Number
- NCT00691938
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
- Conditions
- Multiple MyelomaMyelodysplastic SyndromeAcute Myeloid Leukemia
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-10-22
- Lead Sponsor
- Chroma Therapeutics
- Target Recruit Count
- 57
- Registration Number
- NCT00689000
- Locations
- 🇬🇧
Nexus Oncology Ltd, Edinburgh, Scotland, United Kingdom
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
- Conditions
- Leukemia, Acute MyeloidMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT00687323
Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Gemin X
- Target Recruit Count
- 18
- Registration Number
- NCT00684918
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸The University of Iowa, Iowa City, Iowa, United States
🇺🇸University of Kansas Medical Center Research Institute, Westwood, Kansas, United States
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00666497
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦Diamond Centre, Leukemia/BMT Program of BC, Vancouver, British Columbia, Canada
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
- Conditions
- Adult T Cell Leukemia (ATL)Chronic Myeloid Leukemia (CML-BP)Chronic Lymphocytic Leukemia (CLL)Chronic Myelomonocytic Leukemia (CMML)LeukemiasAcute Myeloid Leukemia (AML)Acute Lymphocytic Leukemia (ALL)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Erimos Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00664677
- Locations
- 🇺🇸
UNC, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 106
- Registration Number
- NCT00656617
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Viron Therapeutics Inc
- Target Recruit Count
- 25
- Registration Number
- NCT00655395
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States